HBV相关HCC治疗的突破：免疫检查点抑制剂的无与伦比的潜力
Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.
摘要(中文译文)
免疫检查点抑制剂通过恢复T细胞介导的抗肿瘤免疫，重塑了肝细胞癌的治疗格局。然而，单药治疗的临床获益仍然有限，凸显了改进患者分层和更有效治疗策略的必要性。HBV相关肝细胞癌（HBV-HCC）是一种主要的病因学亚型，其特征是由持续性病毒抗原暴露和免疫耗竭驱动的慢性免疫抑制性肿瘤微环境。我们认为，HBV-HCC患者可能更适合接受免疫治疗，尤其是免疫检查点抑制剂治疗。深入理解抑制性检查点和共刺激分子的表达模式，结合预测性生物标志物的识别以及有效联合免疫治疗的开发，对于改善临床结局至关重要。从安全性角度来看，在免疫治疗的同时给予适当的抗病毒治疗，乙型肝炎病毒再激活通常是可控的。因此，HBV-HCC患者不应被排除在免疫检查点抑制剂治疗之外。我们预期，包括多靶点免疫检查点阻断、与其他免疫治疗方法的联合以及基于微生物组的治疗在内的联合策略，将进一步提升HBV-HCC的治疗疗效。联合免疫检查点治疗可能增强抗肿瘤应答，并可能有助于更好地控制病毒活动。
Abstract
Immune checkpoint inhibitors have reshaped the therapeutic landscape of hepatocellular carcinoma by restoring T cell-mediated antitumor immunity. However, the clinical benefit of monotherapy remains limited, highlighting the need for improved patient stratification and more effective treatment strategies. HBV-related hepatocellular carcinoma (HBV-HCC) is a major etiological subtype characterized by a chronically immunosuppressive tumor microenvironment driven by persistent viral antigen exposure and immune exhaustion. We believe that patients with HBV-HCC may be more suitable for immunotherapy, especially treatment with immune checkpoint inhibitors. A deeper understanding of the expression patterns of inhibitory checkpoint and costimulatory molecules, along with the identification of predictive biomarkers and the development of effective combination immunotherapies is essential for improving clinical outcomes. From a safety perspective, hepatitis B virus reactivation is generally manageable when appropriate antiviral therapy is administered concurrently with immunotherapy. Consequently, patients with HBV-HCC should not be excluded from treatment with immune checkpoint inhibitors. We anticipate that combination strategies, including multi-target immune checkpoint blockade, combinations with other immunotherapeutic approaches, and microbiome-based therapy, will further enhance therapeutic efficacy in HBV-HCC. Combination immune checkpoint therapy may enhance antitumor responses and potentially contribute to better control of viral activity.
如何引用
AMA
Chenlu Liu, Le Chang, Ying Yan, Huimin Ji, Jie Ma, Huizhen Sun, et al. Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.. Current treatment options in oncology. 2026; doi:10.1007/s11864-026-01395-z.
APA
Chenlu Liu, Le Chang, Ying Yan, Huimin Ji, Jie Ma, Huizhen Sun, et al (2026). Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.. Current treatment options in oncology. https://doi.org/10.1007/s11864-026-01395-z
GB/T 7714
Chenlu Liu, Le Chang, Ying Yan, Huimin Ji, Jie Ma, Huizhen Sun, et al. Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.[J]. Current treatment options in oncology, 2026 doi:10.1007/s11864-026-01395-z.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出